STAT1 modification improves therapeutic effects of interferons on lung cancer cells

Abstract

BackgroundInterferons (IFNs) have potent anti-proliferative, pro-apoptotic, and immunomodulatory activities against cancer. However, the clinical utility of IFNs is limited by toxicity and pharmacokinetics making it difficult to achieve sustained therapeutic levels especially in solid tumors.MethodsSignal Transducer and Activator of Transcription 1 (STAT1) or a modified STAT1 (designated STAT1-CC) that is hyper-responsive to IFN were overexpressed in lung cancer SPC-A-1 and H1299 cells using lentiviral vectors. Transduction efficiency was monitored using enhanced green fluorescent protein (EGFP) expression. After transduction, cells were treated with interferon-gamma (IFN-γ) or interferon-beta (IFN-β) and monitored for cell proliferation, migration, and invasiveness using Cell Counting Kit-8 and transwell chamber assays and for apoptosis using Annexin V detection by flow cytometry. In addition, levels of STAT1, STAT1 Tyr-701 phosphorylation (pSTAT1), fibronectin, and β-catenin were determined using western blotting. In the case of IFN-γ stimulation, levels of S100A4, proliferating cell nuclear antigen (PCNA), and c-fos expression were also determined.ResultsWe found that expression of STAT1 or STAT1-CC enhanced the effect of IFN-γ and, IFN-β on inhibition of human lung cancer cell proliferation, migration and invasiveness. Moreover, STAT1 and STAT1-CC expression caused increases in pSTAT1 and decreases in fibronectin and β-catenin levels. STAT1-CC showed increased effects compared to STAT1 on IFN-γ induced pSTAT1 and down-regulation of S100A4, PCNA, and c-fos levels.ConclusionThe results show that STAT1-CC exhibited more strength in improving the antitumor response of IFNs in lung cancer cells. Results from this study suggest that combined treatment of IFNs and STAT1-CC might be a feasible approach for the clinical management of lung cancer in the future.

Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: a systematic analysis

“…4f-g, STAT1 and CD86 were negatively regulated by YTHDF1. Previous studies demonstrated that the loss of STAT1 activation or expression was found in malignant cells derived from various tumors, while the loss of CD86 expression resulted in a decrease in tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma [30][31][32][33][34][35]. YTHDF1 Fig.…”

Fascin1 suppresses RIG-I–like receptor signaling and interferon-β production by associating with IκB kinase Ε (IKKΕ) in colon cancer

“…Because IKK⑀ directly phosphorylates STAT1 (36) and exerts antitumor activity (37,38), we investigated how fascin1 affects STAT1 phosphorylation in the IFN feedback loop. RIG-I facilitates the positive feedback loop of type I IFN production (39).…”

Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus

“…INS-1 cells were seeded into 96-well plates at a density well and preincubated for 24 h in an incubator at 37°C. Cell viability was assayed using a Cell Counting Kit-8 (CCK-8) assay kit (Dojin Laboratories, Kumamoto, Japan)according to the manufacturer's protocol(32).…”